Descripción de la oferta:

 Buscamos una persona para cubrir el puesto vacante de Enfermero/a en la Unidad de Ensayos Clínicos en Oncología en el Instituto Vall d’Hebron de Oncología (VHIO), Barcelona, ​​España.

Buscamos una persona para realizar las siguientes tareas:

• Preparación del Servicio para el inicio de la jornada.
• Administración de los diferentes tratamientos y procedimientos de ensayo clínico que por protocolo se hagan en el Hospital de Día (trato diario con los pacientes y toma de constantes, realización y envío de ECG y obtención de muestras).
• Control de efectos secundarios.
• Actuación por reacción adversa o situaciones de emergencia.
• Programación de la reserva de sillón de tratamiento para los pacientes en ensayo.
• Proporcionar el diario del paciente.
• Realización y entrega de minimentals y calidades de vida.
• Participación en las visitas de inicio y elaboración de las hojas de enfermería.
• Actualización de la enmiendas de cada protocolo.
• Reuniones periódicas con el coordinador de Enfermería.
• Revisión del carro de paros.
• Control del archivo de la Unidad.
• Almacenamiento y control de stock del material de Enfermería.

 Requisitos:

• Estudios con nivel de grado en Enfermería
• Se valorará experiencia previa en ensayos clínicos y/o oncología
• Catalán, castellano e inglés hablado y escrito

Información adicional:

 Se ofrece la posibilidad de incorporarse en un equipo de trabajo comprometido para velar por la calidad de vida del paciente con cáncer. Debe de mostrar un alto grado de sensibilidad y humanismo, habiendo de estar preparados para afrontar posibles reacciones adversas al formar parte de las investigaciones.

 Lugar de presentación de las ofertas: Enviar Candidaturas a través del formulario o enviando un correo electrónico a selecciorrhh@vhio.net, con asunto “Ref. 07/2019”.

Sobre VHIO:

Bajo la dirección de Josep Tabernero, el Vall d´Hebron Instituto de Oncología (VHIO), creado por José Baselga en 2006, se ha consolidado como un centro oncológico integral de probada excelencia internacional. Gracias a la dirección de Josep y a la óptima estructura organizativa del VHIO, basada en un modelo puramente multidisciplinario y traslacional, los profesionales del VHIO continúan anticipándose y abordando las numerosas cuestiones no resueltas para combatir esta enfermedad heterogénea y multifacética.

Ubicado en el Vall d´Hebron Barcelona Hospital Campus, nuestros investigadores colaboran e interactúan estrechamente con los médicos y científicos de Vall d´Hebron. La ciencia traslacional y la investigación clínica están, por lo tanto, estrechamente conectadas, lo que favorece una excelente interacción y el trabajo en equipo que, a su vez, acelera el ciclo de conocimiento desde la investigación hasta el desarrollo de nuevos tratamientos. Este entorno privilegiado permite el acceso directo por parte del VHIO a los pacientes, así como a todo el espectro de profesionales de oncología que los atienden, y una comprensión inigualable de cómo la ciencia oncológica se puede traducir en tratamientos más potentes y específicos y mejores prácticas para el cuidado de los pacientes.

El modelo y los programas pioneros del VHIO, junto con su convicción en la combinación de capacidades a través de colaboraciones transfronterizas, continúan impulsando avances para revertir la resistencia al cáncer, detener la diseminación metastásica y tratar de manera más eficaz incluso los tipos de tumores más resistentes a los fármacos.

Traslación del VHIO hacia la oncología de precisión: http://www.vhio.net

[contact-form-7]

• Successful intravenous systemic administration of Omomyc against non-small cell lung cancer brings this novel anti-cancer therapy closer to the clinic for the more effective treatment of multiple tumor types

Cutting-edge sequencing technology has revolutionized cancer diagnosis and since identified several so-called cancer driver genomic aberrations. This has led to the development of an extensive and powerful arsenal of anti-cancer therapies that is progressively extending cancer survival rates and reducing mortality from this disease. However, many patients unfortunately become resistant to treatments and suffer disease recurrence.

The MYC oncogene is a transcription factor implicated in multiple biological processes including cell proliferation, metabolism and apoptosis and is a central node of several altered pathways in cancer. Found deregulated in most, if not all, tumor types, aberrantly high activity of MYC correlates with aggressiveness of disease. However, up until now, attempts aimed at inhibiting MYC have fallen short.

For more than twenty years, Laura Soucek, Principal Investigator of VHIO’s Mouse Models of Cancer Therapies and ICREA Professor, has centered her research on the ambitious route towards combating resistance to current therapies and disease progression by clinically inhibiting MYC. Since her arrival at VHIO, her pioneering research using Omomyc-expressing transgenic mice has revealed the anti-cancer activity against several tumor types, including pancreatic cancer and glioblastoma, with mild, manageable and reversible side effects.

These preclinical successes subsequently led to the creation of VHIO born spin-off Peptomyc S.L. in 2014, co-founded by Laura and Marie-Eve Beaulieu, Chief-Scientific-Officer and former postdoctoral researcher of her group.

Published online ahead of print today in Science Translational Medicine*, findings first-authored by Marie-Eve Beaulieu* evidence the Omomyc mini-protein as the first efficient and tolerable MYC inhibitor for the treatment of non-small cell lung cancer (NSCLC) – one of the most difficult-to-treat cancers for both women and men.

30% of these tumors present MYC amplification, while the rest usually display other alterations in intracellular pathways that ultimately lead to deregulated MYC activity. In this present study, Laura’s team show that the mini-protein is active against diverse mutational profiles that are usually resistant to current therapies.

Commenting for VHIO Communications Laura Soucek, last and corresponding author of this study, explained, “NSCLC accounted for around two million cancer-related deaths worldwide in 2018 because of a lack of effective therapies. For instance, patients with KRAS-mutant NSCLC are among the most resistant to standard therapies, but we have shown that Omomyc is effective in treating them too. In fact, we have not yet detected any genomic alteration that impairs Omomyc activity.”

For the very first time the authors establish that the Omomyc mini-protein can be purified and administered in vivo, rapidly reaching the tumor site. Results show that it successfully inhibits its target, leads to reduced tumor grade and promotes regression of existing disease.

They also demonstrate that Omomyc localizes in the lungs within the first 30 minutes after intranasal administration, where it is predominantly restrained within the tumors and persists inside the nuclei of tumor cells 24h post-administration. These findings ring in this promising therapy as new anti-cancer weaponry for the treatment of non-small cell lung cancer, and the first ever viable inhibitor of Myc.

“Intranasal administration was the first proof-of-concept that Omomyc could be delivered as a drug as opposed to being used as gene therapy. However, this means of administration was limited to primary lung tumors but not to the metastases or other primary ones, that is why it was important for us to show that the mini-protein could also be administered systemically,” observed Marie-Eve.

Thanks to Marie-Eve’s particular expertise in peptide design and production, the team succeeded in scaling up the purification process of the mini-protein and re-assessing its therapeutic activity via intravenous administration. Its systemic delivery unleashes the anti-cancer potential of Omomyc and extends its application to the treatment of other tumors and metastases.

Not only did this therapy impair tumor growth in subcutaneous NSCLC xenografts in mice, but also synergized with current standard treatments including paclitaxel. It was also well-tolerated with no sign of the frequently observed side effects due to drug-drug interactions.

Mechanistically, the researchers report that the Omomyc mini-protein harbors cell-penetrating features that enable its internalization into the nuclei and impede the binding of MYC to gene promoters throughout the genome. It specifically downregulates MYC transcriptional programs and avoids undesired activity on other proteins and adverse events in mice.

“Our approach differs completely to other previous attempts aimed at MYC inhibition. This Omomyc mini-protein is large enough to accurately fold and adapt to MYC’s disordered structure, which determines the specificity of inhibition. But, at the same time, it is small enough to penetrate tumor cells and nuclei in order to reach its target,” added Marie-Eve.

Additionally, the researchers have revealed some of the several biologic uptake pathways that are implicated in this process. “We have discovered that one of the main entrance mechanisms of Omomyc is macropinocytosis, which is a cell mechanism to capture nutrients from the microenvironment. It appears that Omomyc hijacks this process and behaves as a ‘Trojan Horse’ to penetrate the tumor cell and kill it,” commented Laura.

Finally, as has been advanced in this publication, the authors suggest that Omomyc may attack tumors not only through the blocking of proliferation and the induction of apoptosis, but also by triggering an immune response. The inhibitor can alter the profile of molecules released by cancer to trick the immune system, and may increase the infiltration of T lymphocytes into the tumor.

This is currently extremely relevant since immunotherapy is showing increasing promise in the treatment of several tumor types, but not all. The capacity of Omomyc to recruit immune cells at the tumor site, ‘spoilered’ in this study, indicates that it could also synergize and resensitize resistant tumors to immune-based therapies.

This translational study represents an important forward step in driving the Omomyc mini-protein closer to the clinic. “This work will hopefully help propel our Omomyc mini-protein as a powerful therapy to treat a wide range of tumor types with distinct mutational profiles,” concluded Laura.

###

* Beaulieu et al, Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-Myc therapy. Science Translational Medicine, 2019. doi/10.1126/scitranslmed.aar5012.

This study has mainly been supported by grants received from the Worldwide Cancer Research and the European Research Council, as well as private funding from the BBVA Foundation and the FERO Foundation.

 Review of applications will commence immediately.

 Position description:

 The Vall d´Hebron Institute of Oncology´s (VHIO) Tumor Immunology and Immunotherapy Group, headed by Dr. Alena Gros, is currently recruiting for a Scientific Laboratory Technician to validate the expansion of tumor-infiltrating lymphocytes (TILs) for patient treatment in good manufacturing practice conditions. The successful candidate will work between Dr. Gros’ lab (VHIO) and the Blood and Tissue Bank (Poble Nou, Barcelona) and, working with team at the Blood and Tissue Bank, will support the expansion of TILs in GMP conditions and contribute to the generation of TIL products for the treatment of patients.

We seek:

A very organized, motivated, team-oriented individual, who is highly skilled in cell/tissue culture and processing. The ideal candidate should be familiar with ELISA, ELISpot, flow-cytometry, and comfortable working with human blood and tissues. Previous experience working in cGMP conditions is preferred.

 Application:

Candidates must submit a curriculum vitae and letter of intent addressed to Dr. Alena Gros using the form below or via email to: selecciorrhh@vhio.net, adding “Ref. 06/2019” in the subject line.

 About VHIO:

Under the leadership of Josep Tabernero, the Vall d’Hebron Institute of Oncology (VHIO), created by José Baselga in 2006, has established itself as a comprehensive cancer center of proven excellence internationally. It is thanks to Josep Tabernero’s directorship and VHIO’s optimal organizational structure based on a purely multidisciplinary and translational model that VHIO talents continue to anticipate and tackle the many unresolved questions in combatting this multifaceted and heterogeneous disease.

Located within the Vall d’Hebron Barcelona Hospital Campus, our researchers closely collaborate and interact with Vall d’Hebron physician-scientists. Translational science and clinical research are therefore tightly connected which promotes superb interaction and teamwork which, in turn, accelerates the bench-bedside-bed cycle of knowledge. This privileged environment affords VHIO direct access to patients as well as the entire spectrum of oncology professionals who care for them, and a second-to-none appreciation of how cancer science can translate into more powerful, targeted treatments and better practice for the care of patients.

VHIO’s pioneering model and programs, coupled with its belief in combining strengths through cross-border collaborations, continue to spur advances in reversing cancer resistance, halting metastatic spread, and more effectively treating even the most undruggable tumor types.

VHIO’s translation toward precision oncology: http://www.vhio.net.

[contact-form-7]

Both journals are part of a family of more than 40 chemistry journals the Royal Society of Chemistry publishes. Catalysis Science & Technology is a multidisciplinary journal for the publication of cutting-edge developments focusing on all fundamental science and technological aspects of catalysis. Lead by Javier Pérez-Ramírez, former ICIQ group leader, the journal publishes research in the applied, fundamental, experimental and computational areas of catalysis. Green Chemistry is at the frontiers of this interdisciplinary science and publishes research that attempts to reduce the environmental impact of chemical processes by developing technologies that are inherently non- or less-toxic to the environment. Articles published in this journal are intended to be conceptually accessible to a wide audience focusing on sustainbility.

 Number of vacancies: 1

Position Summary:

VHIO’s Molecular Oncology Group, directed by Paolo Nuciforo, is now recruiting for a Digital Pathology Scientist to work with its scientists in applying commercial, open-source, and custom software towards streamlined image analysis strategies.

The appointed candidate will contribute to every stage of the image analysis pipeline, including data management, selection of investigative approach, and presentation of results. He/she will also provide technical guidance to VHIO faculty without training in digital pathology to leverage commercial image analysis tools, and help to ensure that quantitative summaries of imaging data are always of the highest quality.

Key responsibilities:

The successful candidate will serves as technical lead for the design and development of innovative algorithms to analyze histopathology images and data.

Key duties include:

• Conceiving, planning, and executing projects; defining project requirements, deliveries, and time lines; tracking progress and ensuring quality results on time.
• Customizing and running software pipelines for specialized image analysis tasks.
• Compiling and producing summary spreadsheets, plots, visualizations, and reports of image-derived data.
• Providing quality assurance/quality control of image analysis results.
• Streamlining workflows for batch processing, data collation, results management, QC, etc.
• Keeping up-to-date with – and assessing – technology advances, the competitive landscape, and job training requirements in the field of digital pathology.
• Providing technical direction, guidance and feedback to other VHIO faculty.
• Evaluating technology requirements for algorithm development and making recommendations.
• Running algorithm feasibility for new projects.

Additional duties as may be assigned by the group’s Principal Investigator towards delivering on their program’s operational goals.

Essential qualifications:

Formal Training/Education:

• M.S. Degree (Ph.D. favorably considered) in Computer Science, Biomedical Engineering, Electrical Engineering, or a related field.

Experience and Required Skills:

• At least two years’ academic or industry R&D experience with software development for image or data analysis algorithms.
• Expert understanding of biomedical image data, especially pathology images and digital pathology imaging modalities.
• Deep understanding of fundamental image processing concepts such as image registration, segmentation, classification, pattern recognition, machine learning, etc.
• Experience in using image analysis software such as QPath, ImageJ, Visiopharm, Indica Labs HALO, or others.
• 2+ years’ programming experience (Python, Matlab, C++, or similar); experience applying machine learning techniques (e.g. SVM with hand-crafted features; CNN for supervised classification of images; clustering methods for unsupervised learning).
• Exceptional critical thinking, attention to detail, scientific rigor, and strong analytical, problem solving, and troubleshooting skills.
• Ability to multi-task across multiple projects while still meeting deadlines.
• Capacity to work independently as well as collaboratively as part of a larger project.
• A positive attitude, keen will to learn new things as well as help others.

Application: Please send your CV and cover letter highlighting your scientific interests either using the form below, or emailing us at: selecciorrhh@vhio.net, adding “Ref. 05/2019” in the subject box of your email.

About VHIO:

Under the leadership of Josep Tabernero, the Vall d’Hebron Institute of Oncology (VHIO), created by José Baselga in 2006, has established itself as a comprehensive cancer center of proven excellence internationally. It is thanks to Josep Tabernero’s directorship and VHIO’s optimal organizational structure based on a purely multidisciplinary and translational model that VHIO talents continue to anticipate and tackle the many unresolved questions in combatting this multifaceted and heterogeneous disease.

Located within the Vall d’Hebron Barcelona Hospital Campus, our researchers closely collaborate and interact with Vall d’Hebron physician-scientists. Translational science and clinical research are therefore tightly connected which promotes superb interaction and teamwork which, in turn, accelerates the bench-bedside-bed cycle of knowledge. This privileged environment affords VHIO direct access to patients as well as the entire spectrum of oncology professionals who care for them, and a second-to-none appreciation of how cancer science can translate into more powerful, targeted treatments and better practice for the care of patients.

VHIO’s pioneering model and programs, coupled with its belief in combining strengths through cross-border collaborations, continue to spur advances in reversing cancer resistance, halting metastatic spread, and more effectively treating even the most undruggable tumor types.

VHIO’s translation toward precision oncology: http://www.vhio.net.

[contact-form-7]